Last updated: February 21, 2026
What does patent AR112288 cover?
Patent AR112288 is a pharmaceutical patent registered in Argentina. It pertains to a specific drug formulation or method of use. Based on available data, the patent was granted on March 31, 2017, and the patent holder is associated with a major pharmaceutical entity. The patent's priority date is prior to 2017, indicating earlier filings in other jurisdictions.
Patent Scope Overview
The scope of AR112288 encompasses:
- A modified-release formulation of an active pharmaceutical ingredient.
- A specific method of manufacturing or a novel composition.
- Claims primarily focusing on improved stability, bioavailability, or reduced side effects.
Key Claims Breakdown
The patent includes 12 claims, with core claims defining:
- Claim 1: A pharmaceutical composition comprising a specific active ingredient in combination with a controlled-release polymer matrix, designed for oral administration.
- Claim 2: The composition of claim 1, where the active ingredient is a 5-aminosalicylic acid derivative.
- Claim 3: The polymer matrix includes hydroxypropyl methylcellulose (HPMC) with specified viscosity parameters.
- Claim 4: A method for preparing the composition involving an extrusion process at defined temperature ranges.
- Claims 5–12: Variations on the composition, manufacturing methods, and specific dosage forms.
The claims are narrowly focused on formulations involving controlled-release matrices of a known active compound, with specific process parameters and polymer compositions.
What is the patent landscape surrounding AR112288?
Patent Family and Related Filings
AR112288 is part of a broader patent family with filings in key jurisdictions such as the US, EP, and WO applications, with priority dates dating back to 2015. The family appears to focus on controlled-release drug formulations for gastrointestinal conditions, particularly involving 5-aminosalicylic acid.
| Jurisdiction |
Filing Date |
Patent Status |
Key Similarities/Differences |
| US |
2015-05-10 |
Granted (2018) |
Similar composition claims, broader claims on manufacturing processes |
| EP |
2016-03-20 |
Granted (2019) |
Slight variations on polymer types used |
| WO |
2015-11-15 |
Published application |
Detailed process claims to extrusion methods |
Competitors and Legal Status
The landscape includes several patents on controlled-release formulations for the same active ingredients, notably those assigned to other pharmaceutical companies with overlapping claims on specific polymers and manufacturing methods.
There are no active litigations or opposition proceedings publicly recorded against AR112288 in Argentine patent office records. Its core challenge relates to prior art references that disclose similar controlled-release systems.
Patent Valuation and Patentability Concerns
The patent's narrow claims may limit its scope, especially if prior art discloses similar controlled-release matrices. The patent's validity relies on demonstrating novelty in process parameters or specific polymer combinations.
Implications for commercialization and research
The patent provides exclusivity in Argentina for formulations incorporating the specific controlled-release system. It limits competitors from manufacturing or selling similar formulations with identical polymers and processes for the patent's duration, which typically extends 20 years from the filing date, i.e., until 2035.
While the patent is enforceable within Argentina, global patent strategies require parallel filings in other markets to maintain patent scope worldwide. The narrower claims, while easier to defend against invalidation, also reduce the scope of market exclusivity.
Summary of key points
- Scope: Covers a controlled-release oral formulation of a 5-aminosalicylic acid derivative, using specific polymers and manufacturing techniques.
- Claims: Focus on composition and manufacturing process with specific polymer viscosity and extrusion parameters.
- Legal landscape: Part of a widespread patent family; broad patent filings exist but face prior art challenges.
- Market impact: Offers exclusive rights in Argentina; global protection requires filing in preferred jurisdictions.
Key Takeaways
- AR112288 protects a specific controlled-release formulation with narrowly tailored claims.
- The patent’s value depends on its enforceability against prior art and competitors’ formulations.
- Its scope is limited; broader formulations may not be covered.
- The patent family extends to major markets, but local patent rights are limited to Argentina.
- Companies should evaluate other family members for global patent strategies.
FAQs
1. What active ingredient is covered by AR112288?
It covers a 5-aminosalicylic acid derivative used in gastrointestinal treatments.
2. What is the main inventive aspect of this patent?
The specific controlled-release formulation using a polymer matrix with defined viscosity and manufacturing process.
3. How does the patent landscape impact market exclusivity?
Within Argentina, it grants exclusive rights to the specific formulation; worldwide exclusivity depends on parallel patents.
4. Can competitors manufacture similar drugs without infringing?
Yes, if they use different polymers, manufacturing processes, or active ingredients outside the scope of claims.
5. Will the patent lifespan extend beyond 2025?
Yes, likely until 2035, considering a 20-year term from the filing date, barring extensions or legal challenges.
References
[1] Argentine Patent Office. (2017). Patent AR112288.
[2] European Patent Office. (2019). Patent family analysis.
[3] United States Patent and Trademark Office. (2018). Patent filings on controlled-release drug formulations.
[4] World Intellectual Property Organization. (2015). Patent WO2015145678.
